Exploring the Attitudes, Barriers, Concerns, Differences, and Ethics (ABCDEs) of Healthcare Decision Making of Vagus Nerve Stimulation
- 1University of Minnesota, Department of Psychiatry and Behavioral Health Sciences
Abstract
Vagus nerve stimulation (VNS) is an established neuromodulation therapy approved for treatment-resistant depression (TRD) and epilepsy, with growing interest in its application to other conditions. Despite demonstrated clinical efficacy, VNS remains underused in psychiatric care. This mixed-methods study examined stakeholder perceptions of VNS, focusing on access, stigma, ethical concerns, and acceptability across epilepsy, depression, heart failure (HF), and rheumatoid arthritis (RA). We conducted six focus groups and 20 semi-structured interviews with patients, clinicians, and one support person, and integrated qualitative themes with quantitative data on stigma and treatment barriers. Participants revealed stark disparities in VNS adoption: epilepsy patients reported fewer insurance barriers, while TRD participants faced delayed approvals, high out-of-pocket costs, and limited access to specialty care. Depression stakeholders reported higher stigma scores and expressed greater reluctance to consider surgical treatment, despite possessing comparable knowledge to epilepsy stakeholders. Ethical concerns, particularly regarding informed consent and impaired decision-making, surfaced frequently in the context of TRD. Most participants agreed that the appropriateness of VNS should align with disease severity and impact on quality of life. Many cautiously supported VNS for HF and RA, provided strong efficacy data supports its use. Hope emerged as a consistent theme, especially among TRD participants seeking alternatives after exhausting other treatments. These findings underscore the need to address insurance barriers, reduce stigma, and enhance provider education. As VNS expands into new indications, policymakers and clinicians must implement reforms that promote equitable access, decentralized care, and ethically sound consent practices to ensure inclusive neuromodulation therapy adoption.
Related
- Exploring the barriers to prehabilitation integration in Austrian healthcare: a qualitative analysis
- Healthcare professionals’ knowledge, attitudes, and practices regarding perioperative ischemic stroke in elderly patients
- Knowledge, attitudes and behaviours toward evidence-based practice among healthcare professionals in Kuwait: a cross-sectional study
- Knowledge, attitudes, and practices regarding cystic echinococcosis among healthcare students and intern doctors in the west bank: a cross-sectional study
- Ultrasound stimulation of hindlimb skeletal muscle is associated with selective differences in splenic metabolites during hindlimb unloading in mice
BibTeX
@misc{sullivan2026exploring,
title = {{Exploring the Attitudes, Barriers, Concerns, Differences, and Ethics (ABCDEs) of Healthcare Decision Making of Vagus Nerve Stimulation}},
author = {C. R. Sullivan and L. R. Caola and R. A. Johnson and C. Differding and A. Randolph and A. Mejia and D. Balangoy and A. S. Widge and T. R. Henry and Z. Nahas and L. Y. Cabrera and S. R. Wilson},
howpublished = {medRxiv},
year = {2026},
month = oct,
doi = {10.64898/2026.10.27.26366559},
url = {https://www.medrxiv.org/content/10.64898/2026.10.27.26366559v1},
note = {CC BY},
}
RIS
TY - UNPB
TI - Exploring the Attitudes, Barriers, Concerns, Differences, and Ethics (ABCDEs) of Healthcare Decision Making of Vagus Nerve Stimulation
AU - C. R. Sullivan
AU - L. R. Caola
AU - R. A. Johnson
AU - C. Differding
AU - A. Randolph
AU - A. Mejia
AU - D. Balangoy
AU - A. S. Widge
AU - T. R. Henry
AU - Z. Nahas
AU - L. Y. Cabrera
AU - S. R. Wilson
PY - 2026
DA - 2026/10/27
PB - medRxiv
DO - 10.64898/2026.10.27.26366559
UR - https://www.medrxiv.org/content/10.64898/2026.10.27.26366559v1
AB - Vagus nerve stimulation (VNS) is an established neuromodulation therapy approved for treatment-resistant depression (TRD) and epilepsy, with growing interest in its application to other conditions. Despite demonstrated clinical efficacy, VNS remains underused in psychiatric care. This mixed-methods study examined stakeholder perceptions of VNS, focusing on access, stigma, ethical concerns, and acceptability across epilepsy, depression, heart failure (HF), and rheumatoid arthritis (RA). We conducted six focus groups and 20 semi-structured interviews with patients, clinicians, and one support person, and integrated qualitative themes with quantitative data on stigma and treatment barriers. Participants revealed stark disparities in VNS adoption: epilepsy patients reported fewer insurance barriers, while TRD participants faced delayed approvals, high out-of-pocket costs, and limited access to specialty care. Depression stakeholders reported higher stigma scores and expressed greater reluctance to consider surgical treatment, despite possessing comparable knowledge to epilepsy stakeholders. Ethical concerns, particularly regarding informed consent and impaired decision-making, surfaced frequently in the context of TRD. Most participants agreed that the appropriateness of VNS should align with disease severity and impact on quality of life. Many cautiously supported VNS for HF and RA, provided strong efficacy data supports its use. Hope emerged as a consistent theme, especially among TRD participants seeking alternatives after exhausting other treatments. These findings underscore the need to address insurance barriers, reduce stigma, and enhance provider education. As VNS expands into new indications, policymakers and clinicians must implement reforms that promote equitable access, decentralized care, and ethically sound consent practices to ensure inclusive neuromodulation therapy adoption.
ER -